1-5 of 5
Yun Kyoung Ryu
Close
Sort by
Journal Articles

Combination Epigenetic Therapy Using YF2, a First-in-Class Histone Acetyltransferase Activator, Restores Immunogenicity in Diffuse Large B-Cell Lymphoma

Ted B. Piorczynski, Yun Kyoung Ryu, Manuel Pazos, II, Wenxuan Huang, Seda S. Tolu, Brian Estrella, Jennifer E Amengual
Journal: Blood
Blood (2023) 142 (Supplement 1): 4391.
https://doi.org/10.1182/blood-2023-179271
Published: 2023
Journal Articles

First-in-Class HAT Activator (YF2) Combined with JAK/STAT Inhibitor (ruxolitinib) Unveils Potential Novel Treatment Approach for HDAC Inhibitor-Resistant CTCL

Manuel Pazos, II, Brian Estrella, Ted B. Piorczynski, Seda S. Tolu, Wenxuan Huang, Yun Kyoung Ryu, Jennifer E Amengual
Journal: Blood
Blood (2023) 142 (Supplement 1): 4184.
https://doi.org/10.1182/blood-2023-186639
Published: 2023
Journal Articles

JAK1/2 Inhibition Modulates Key Markers of Lymphomagenesis in 9p24.1 Amplified Lymphoma, Priming for Enhanced Antigenicity

Seda S. Tolu, Ted B. Piorczynski, Manuel Pazos, II, Brian Estrella, Wenxuan Huang, Yun Kyoung Ryu, Hua-Jay J. Cherng, Barbara Pro, Jennifer E. Amengual
Journal: Blood
Blood (2023) 142 (Supplement 1): 6118.
https://doi.org/10.1182/blood-2023-180875
Published: 2023
Journal Articles

First-in-Class Histone Acetyltransferase (HAT) Activator, YF2, Modulates Immune Evasion in DLBCL, Enhancing the Effects of Immune Checkpoint Blockade

Brian Estrella, Manuel A Pazos, II, Edd C Ricker, Yun Kyoung Ryu, Ted B. Piorczynski, Yuxuan Liu, Seda Tolu, Jennifer E. Amengual
Journal: Blood
Blood (2022) 140 (Supplement 1): 358–359.
https://doi.org/10.1182/blood-2022-166929
Published: 2022
Journal Articles

Daratumumab Plus Chemotherapy Induces Complete Responses in a Consecutive Series of Four Patients with Plasmablastic Lymphoma

Edd C Ricker, Yun Kyoung Ryu, Jennifer E. Amengual
Journal: Blood
Blood (2021) 138 (Supplement 1): 4573.
https://doi.org/10.1182/blood-2021-150800
Published: 2021